Document:

Amendment No. 2 to Commercial License Agreement

 EXHIBIT 10.1 
  
 AMENDMENT NO. 2 TO COMMERCIAL LICENSE AGREEMENT 
  
 THIS AMENDMENT NO. 2 (“Amendment No. 2”), effective as of October 4, 2005 (the “Amendment Effective
Date”), is made by and between Xenogen Corporation, having its principal place of business at 860 Atlantic Avenue, Alameda, California 94501 (“Xenogen”) and Novartis Institutes for BioMedical Research, Inc., having its
principal place of business at 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (“NIBRI”). 
  
 WITNESSETH 
  
 WHEREAS,
Xenogen and IRM, LLC, a Delaware corporation, are parties to a Commercial License Agreement, effective as of July 12, 2000, as amended and extended by the Amendment to commercial License Agreement, made by and between the parties as of
July 12, 2003 (“Amendment No.1”) and further extended by a letter agreement between the parties on August 3, 2005 (the “Extension Letter”) (such Commercial License Agreement, together with Amendment No.1
and the Extension Letter, the “License Agreement”); 
  
 WHEREAS,
NIBRI is an “Affiliate” of IRM and a “Permitted User” under the License Agreement, as the terms “Affiliate” and Permitted User” are defined in the License Agreement; 
  
 WHEREAS, the License Agreement shall expire on October 12, 2005 and the parties wish to
extend the its Term through July 12, 2006; and 
  
 WHEREAS, the parties wish
to amend certain other terms and provisions of the License Agreement; 
  
 NOW,
THEREFORE, the parties agree as follows: 
  

	 	1.	Capitalized terms used but not defined herein shall have the meanings ascribed to them in the License Agreement. 

  

	 	2.	The Term of the License Agreement is hereby extended through July 12, 2006. 

  

	 	3.	NIBRI or an Affiliate will pay to Xenogen a fee of [***] for the period beginning on July 13, 2005 and ending on July 12, 2006 (the “Second Extension
Term”). Such fee will be paid within sixty (60) days after receipt by NIBRI of the related invoice in the form attached as Annex 1 hereof (“Invoice”), which Invoice shall be delivered on or after the Amendment
Effective Date. The payment of such fee by NIBRI or an Affiliate shall be in lieu of the payment of any other fees for the Second Extension Term by IRM, Permitted Users or any assignee pursuant to the License Agreement or Amendment No.1.

  

	[***]	CONFIDENTIAL TREATMENT REQUESTED FOR PORTIONS OF THIS EXHIBIT 

	 	4.	Prior to the end of the Second Extension Term, unless earlier terminated, IRM, Permitted Users or an assignee under Section 11.2 of the License Agreement (the
“Extending Party”) may extend the Second Extension Term for an additional one (1) year period (the “Third Extension Term”) by notifying Xenogen in writing that it is exercising its right to extend. The
Extending Party shall then pay to Xenogen a fee of [***] for the Third Extension Term. Such fee will be paid within sixty (60) days after receipt by the Extending Party of the related Invoice which Invoice shall be delivered on or after the
date on which the Extending party delivers the written notice discussed in the first sentence of this Section 4. The payment of such fee by the Extending Party shall be in lieu of the payment of any other fees for the Third Extension Term by
IRM, Permitted Users or any assignee pursuant to the License Agreement or Amendment No.1. 

  

	 	5.	Xenogen will make available its IVIS Imaging Systems for purchase by IRM or Permitted Users at the prices set forth in Annex 2 or [***] which ever is lower during the Second
Extension Term and for the Third Extension Term, as the case may be. For purpose of this Amendment No. 2, [***]. As applicable and at the discretion of IRM or Permitted Users, Xenogen shall provide notice and refund or credit the difference between
the price paid and [***] 

  

	 	6.	Except as amended hereby, the License Agreement shall remain in full force and effect, according to its terms. 

  

	 	7.	This Amendment No. 2, the License Agreement, Amendment No. 1 and the Extension Letter shall constitute the entire agreement between the parties and shall supersede all other
agreements, whether written or oral, relating to the subject matter hereof. 

  
 IN WITNESS WHEREOF, the parties have entered into this Amendment No. 2 effective as of the Amendment Effective Date, by signatures of their duly authorized officers set forth below. 
  
 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC.

  

			
	 By:
	 	 /s/ MARK C. FISHMAN

	 Name:
	 	 Mark C. Fishman

	 Title:
	 	 President & CEO

  

			
	 XENOGEN CORPORATION

		
	 By:
	 	 /s/ DAVID R. BOYKO, ESQ.

	 Name:
	 	 DAVID R. BOYKO, ESQ.

	 Title:
	 	 VICE PRESIDENT, LICENSING & LEGAL SERVICES

  

	[***]	CONFIDENTIAL TREATMENT REQUESTED FOR PORTIONS OF THIS EXHIBIT 

 ANNEX 1 
 Sample Invoice to Novartis 
  
 [Xenogen
Letterhead] 
  
 [Date] 
  
 Novartis Institutes for BioMedical Research, Inc. 
 250 Massachusetts Avenue 
 Cambridge, MA 02139 
 USA 
  
 Attn: C. Klee 
 Chief Financial Officer 
  
 Dear Mr. Klee 
  
 Re: Amendment No. 2 to Commercial License Agreement 
  
 This is an invoice requesting payment in connection with the above-captioned amendment between Xenogen Corporation and Novartis Institutes for BioMedical Research, Inc. 
  
 Project Contact Persons in Novartis: Lauren Silverman and Peter Lassota 
  
 SPECIFICATION: [describe in reasonable detail the services and dates, or the event, for which
payment is due (e.g 1.Q.2000, 2nd funding year)] 
  

			
	 Amount and Currency:
	  	[                                ]
		
	 Amount of VAT (if applicable):
	  	[                                ]
		
	 Total Amount (including VAT):
	  	[                                ]
		
	 VAT number (if applicable)
	  	[                                ]
		
	 Bank Address and Account No:
	  	[insert the name and address of the bank to which the payment should be sent and the account number to which it should be credited]

  
 Sincerely yours, 
  
 [INSTITUTION] 

 ANNEX 2 
 [***] Price 
  
 IVIS 50 [***] 
 IVIS 100 [***] 
 IVIS200 [***] 
 IVIS 3D [***] 
  

	[***]	CONFIDENTIAL TREATMENT REQUESTED FOR PORTIONS OF THIS EXHIBITAmendment of Solicitation/ Modifcation of Contract

 EXHIBIT 10.2 
  

																									
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT	  	1. CONTRACT ID CODE	  	 PAGE OF PAGES
 1                2

  

																									
				
	2. AMENDMENT/MODIFICATION NO.	  	3. EFFECTIVE DATE	 	4. REQUISITION/PURCHASE REQ. NO.	  	5. PROJECT NO.     (if applicable)
				
	                03	  	            09/24/2005	 	    NA	  	 
		
	6. ISSUED
BY                                     CODE	 	7. ADMINISTERED BY (If other than Item 6)
                    CODE
		
	 National Institute of Environmental Health Sciences
 Acquisitions Management Branch/OM
 P.O. Box 12874
 Research Triangle Park, NC 27709
	 	 OMB No. 0990-0115
         Deltra C. Lunney
         919-541-0387

			
	8. NAME AND ADDRESS OF CONTRACTOR (No. street, city, State and ZIP Code)	  	x	  	9A. AMENDMENT OF SOLICITATION NO.
						
	 	 	 	 	 	 	 	  	 	  	9B. DATED (SEE ITEM 11)
						
	         Xenogen Biosciences
         5 Cedar Brook Drive
         Cranbury, NJ 08512
                 Attn: Stephen McAndrew
	 	 	 	 	 	 	  	 	  	 10A. MODIFICATION OF
 CONTRACT/ORDER
NO.

						
	 	 	 	 	 	 	 	  	x	  	273-03-C-0045
						
	 	 	CR300045	 	B2	 	 	  	 	  	 10B. DATED (SEE ITEM 13)
     9/25/2003

				
	CODE	 	FACILITY CODE	  	 	  	 
	
	11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS
			
	 ̈	 	 The above numbered solicitation is amended as set forth in Item 14.
 The hour and data specified for receipt of Offers.
	 	 ̈ is extended
         ̈ is not extended
		
	 	 	Offers must acknowledge receipt of the amendment prior to the hour and date specified in the specification or as amended, by one of the following methods:
		
	 	 	(a) By completing items 8 and 15, and returning              copies of the amendment (b) by acknowledging receipt
of this amendment on each copy of the offer submitted; or
		
	 	 	(c) By separate letter or telegram which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE RECEIVED AT THE PLACE DESIGNATED FOR
THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by telegram or letter, provided each telegram
or letter makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.
	
	12. ACCOUNTING AND APPROPRIATION DATA (If required)
	
	EIN:    1311122130A2
	
	 13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS/ORDERS.
 IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.

  

													
	 x
	  	 A.     THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN
ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM 10A.

		
	 	  	 B.     THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as
changes in paying office, appropriation date, etc.) SET FORTH IN ITEM 14. PURSUANT TO THE AUTHORITY OF FAR 43,103(B).

		
	 	  	 C.     THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:

		
	 	  	 D.     OTHER (Specify type of modification and authority )

		
	 x
	  	 FAR 43,103(a) Bilateral Modification

  

																					
	
	 E. IMPORTANT: Contractor     ̈ is not,    x is required to sign this document and return    2 copies to the issuing office.

	
	14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) Purpose of this
modification:

  
 1) To
extend the base performance period 
 2) To summarize the impact on award and obligation amounts 
  
 Except as provided herein, all terms and conditions of the document referenced in Item 9A or
10A, as therefore changed, remains unchanged and in full force and effect. 

							
		
	15A. NAME AND TITLE OF SIGNER (Type or print)	 	16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)
				
	     Stephen J. McAndrew, Ph.D.
     Vice President, Business Development
	 	 	 	Antoinette Bridges, Contracting Officer	 	 
				
	15B. CONTRACTOR/OFFEROR	 	15C. DATE SIGNED	 	16B. UNITED STATES OF AMERICA	 	16C. DATE SIGNED
				
	         /S/ STEPHEN J. MCANDREW

	 	9/27/05	 	 /S/ ANTOINETTE BRIDGES

	 	10/7/05
				
	(Signature of person authorized to sign)	 	 	 	(Signature of Contracting Officer)	 	 
			
	 NSN 7540 - 01 - 152 - 8070
 PREVIOUS EDITION
UNUSABLE
	 	 	 	                         STANDARD FORM 30 (REV. 10-83)
                         Prescribed by GSA
                         FAR [40 CFR]
50,243

					
	AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT	  	1. CONTRACT ID CODE	  	 PAGE OF PAGES
 2                2

  
 Contract #:
273-03-C-0045                     Xenogen Biosciences 
 Modification #: 03 
  
 1) The base performance
period is extended from September 24, 2005 to October 31, 2006 to allow for completion and delivery of existing projects. 
  
 2) Summary for Clarification Purposes: 
  
 (a) The completion date of September 24, 2005 is changed to October 30, 2006 by reason of this modification. 
  
 (b) The contract award and obligation amount [***] is unchanged by reason of
this modification. 
  

					
	 	  	Awarded

	  	Obligated

	 Prior to this Modification # 03:
	  	[***]	  	[***]
	 Changed per this Modification 03:
	  	0.00	  	0.00
	 	  	
	  	

	 Current/New Totals:
	  	[***]	  	[***]
			
	 Completion Date: October 30, 2006
	  	 	  	 

	***	CONFIDENTIAL TREATMENT REQUESTED FOR PORTIONS OF THIS EXHIBIT 

  

					
	 NSN 7540 - 01 - 152 - 8070
 PREVIOUS EDITION
UNUSABLE
	 	CONTINUATION PAGE	 	 STANDARD FORM 30(REV. 10-83)
 Prescribed by
GSA
 FAR(40 CFR) 53343

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00093-of-00352.parquet"}]]